Lei Jianping on May 14
InnoCare Pharma Co., Ltd. (company code: 688428, company abbreviation: InnoCare) recently released its financial report. According to the financial report, InnoCare's revenue in 2023 will be 739 million yuan, an increase of 18.09% from 625 million yuan in the same period last year.
InnoCare's existing drug candidates cover a number of promising innovative targets and indications, including small molecule drugs, monoclonal antibodies and bispecific antibodies for the treatment of hematologic tumors, various autoimmune diseases and solid tumors.
During the reporting period, the company's orelabrutinib revenue was: 671 million yuan, an increase of 18.52% over the previous year; The company's total operating income was 739 million yuan, an increase of 18.09% over the previous year; Net loss decreased by $248 million from the year-ago quarter, mainly due to higher operating income and interest income, lower selling expenses, lower foreign exchange losses and higher R&D expenses.
During the reporting period, the company continued to increase investment in the construction of new technology platforms, preclinical research and clinical trials, and the R&D expenses were 757 million yuan, an increase of 16.73% compared with the same period last year.
InnoCare's net loss in 2023 was RMB631 million, compared to RMB887 million in the same period last year, and the net loss after deduction was RMB626 million, compared to RMB0.96 billion in the same period last year.
Among them, InnoCare's revenue in the fourth quarter of 2023 will be 200 million yuan, the net loss will be 100 million yuan, and the net loss after deducting non-profits will be 77.75 million yuan.
Hillhouse is the majority shareholder
截至2023年12月31日,高瓴旗下HHLR及其一致行动人持股为11.83%,King Bridge Investments Limited 及其一致行动人持股9.009%,Sunny ViewHoldings Limited与 Renbin Zhao(赵仁滨、施一公)家族持股为8.2023%,Sunland BioMedLtd 与 Jisong Cui(崔霁松)家族持股7.1391%;
As of December 31, 2023, InnoCare's shareholding structure
Vivo Capital Fund VIII, L.P. and its concert parties hold 7.3243% of the shares, Bank of Communications Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 1.1343% of the shares, Agricultural Bank of China Co., Ltd. - Penghua Pharmaceutical Technology Equity Securities Investment Fund holds 1.0862% of the shares, and Guangzhou High-tech Zone Technology Holding Group Co., Ltd. holds 0.5091% of the shares. Bohai Bank Co., Ltd.-China Securities Construction Investment Investment Medical Reform Flexible Allocation Hybrid Securities Investment Fund holds 0.5048% of the shares.
截至2023年6月30日，高瓴旗下HHLR及其一致行动人持股为11.83%，King Bridge Investments Limited 及其一致行动人持股9.26%，Sunny ViewHoldings Limited与 Renbin Zhao（赵仁滨、施一公）家族持股为8.2%，Vivo Capital Fund VIII,L.P.及其一致行动人持股为7.42%；
As of June 30, 2023, InnoCare's shareholding structure
Sunland BioMed Ltd and Jisong Cui (Cui Jisong) family hold 7.23% of the shares, Bank of Communications Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 1.13%, Agricultural Bank of China Co., Ltd. - Penghua Pharmaceutical Technology Equity Securities Investment Fund holds 0.88%, and Guangzhou High-tech Zone Science and Technology Holding Group Co., Ltd. holds 0.51%. Bank of China Co., Ltd.-E Fund Healthcare Industry Hybrid Securities Investment Fund holds 0.47% of the shares.
The comparison shows that Hillhouse is still a major shareholder, and the overall shareholding ratio has not changed much.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.